Journal of Pathology Informatics Journal of Pathology Informatics
Contact us | Home | Login   |  Users Online: 204  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 


ORIGINAL ARTICLE
Year : 2021  |  Volume : 12  |  Issue : 1  |  Page : 17

Dissecting the business case for adoption and implementation of digital pathology: A white paper from the digital pathology association


1 Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
2 LabCorp Oncology, Burlington, NC, USA
3 Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
4 Department of Pathology, Southern California Permanente Medical Group, La Canada Flintridge, CA, USA
5 Barco, Inc. Wauwatosa, WI, USA
6 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
7 Inform Diagnostics Irving, TX, USA
8 LUMEA Lehi, UT, USA
9 PathAI Boston, MA 02215, USA
10 Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
11 Johns Hopkins Medicine Pathology Informatics, Baltimore, MD 21287, USA
12 Education Services Department, Oracle Corp, Austin, Texas, USA
13 Philips, Best, NL, The Netherlands
14 Inspirata, Inc. Tampa, FL, USA
15 Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
16 Indica Labs Corrales, NM, USA

Correspondence Address:
Jennifer C Quigley
LabCorp Oncology, CMBP, 1912 TW Alexander Drive, Research Triangle Park, NC 27709
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpi.jpi_67_20

Rights and Permissions

We believe the switch to a digital pathology (DP) workflow is imminent and it is essential to understand the economic implications of conversion. Many aspects of the adoption of DP will be disruptive and have a direct financial impact, both in short term costs, such as investment in equipment and personnel, and long term revenue potential, such as improved productivity and novel tests. The focus of this whitepaper is to educate pathologists, laboratorians and other stakeholders about the business and monetary considerations of converting to a digital pathology workflow. The components of a DP business plan will be thoroughly summarized, and guidance will be provided on how to build a case for adoption and implementation as well as a roadmap for transitioning from an analog to a digital pathology workflow in various laboratory settings. It is important to clarify that this publication is not intended to list prices although some financials will be mentioned as examples. The authors encourage readers who are evaluating conversion to a DP workflow to use this paper as a foundational guide for conducting a thorough and complete assessment while incorporating in current market pricing. Contributors to this paper analyzed peer-reviewed literature and data collected from various institutions, some of which are mentioned. Digital pathology will change the way we practice through facilitating patient access to expert pathology services and enabling image analysis tools and assays to aid in diagnosis, prognosis, risk stratification and therapeutic selection. Together, they will result in the delivery of valuable information from which to make better decisions and improve the health of patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1438    
    Printed36    
    Emailed0    
    PDF Downloaded234    
    Comments [Add]    

Recommend this journal